MONTREAL, CANADA--(Marketwire - December 05, 2007) - Theratechnologies (TSX: TH) today announced that the results from its first Phase 3 clinical trial, using tesamorelin (TH9507), are published in the December 6, 2007 New England Journal of Medicine (www.nejm.org). The study entitled, “Metabolic Effects of a Growth Hormone-Releasing Factor in Patients with HIV” outlines, in detail, the 26-week data of the trial. Top-line results of this Phase 3 trial were initially disclosed in December 2006.
